Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 2/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479405 | 0.92 | LMNA (0.68) | LMNAL3MBTL1POLBALDH1A1CYP1A2 | |
| SCHEMBL23914948 | 0.84 | KMT2A (0.60) | LMNAL3MBTL1POLBTDP1ALDH1A1 | |
| SCHEMBL7056985 | 0.83 | LMNA (0.69) | LMNAPOLBTDP1ALDH1A1TSHR | |
| SCHEMBL7745926 | 0.83 | TDP1 (0.51) | LMNATDP1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29324305 | 0.82 | CNR1 (0.48) | LMNATDP1ALDH1A1CRHBPCRHR2 | |
| SCHEMBL8021031 | 0.81 | L3MBTL1 (0.63) | LMNAL3MBTL1TDP1ALDH1A1TSHR | |
| SCHEMBL17023509 | 0.79 | GAA (0.58) | LMNAL3MBTL1POLBALDH1A1CYP1A2 | |
| SCHEMBL8530934 | 0.79 | MEN1 (0.59) | LMNAL3MBTL1POLBALDH1A1CYP1A2 | |
| SCHEMBL18833437 | 0.79 | KMT2A (0.69) | LMNAL3MBTL1POLBTDP1ALDH1A1 | |
| SCHEMBL15956289 | 0.79 | LMNA (0.70) | LMNAL3MBTL1ALDH1A1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | LMNA 449/4885L3MBTL1 2938/4885POLB 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.